Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Busch

Showing results (491-500 of 504) with videos related to

Pageof 51
Sort By:
Communications Biology|November 26, 2020
Large genome-wide association study identifies three novel risk variants for restless legs syndromeMaria Didriksen, Muhammad Sulaman Nawaz, Joseph Dowsett, et al.
Nature Communications|January 23, 2021
SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaquesYashavanth Shaan Lakshmanappa, Sonny R Elizaldi, Jamin W Roh, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2008
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionBrandon F Keele, Elena E Giorgi, Jesus F Salazar-Gonzalez, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
JAMA|September 2, 2021
Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021Jefferson M Jones, Mars Stone, Hasan Sulaeman, et al.
Science (New York, N.Y.)|December 9, 2020
Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemicLewis F Buss, Carlos A Prete, Claudia M M Abrahim, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay AreaDianna L Ng, Gregory M Goldgof, Brian R Shy, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Science Advances|July 31, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Nature Communications|September 18, 2020
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient bloodDianna L Ng, Gregory M Goldgof, Brian R Shy, et al.
Pageof 51

Showing results (491-500 of 504) with videos related to

Sort By:
Pageof 51
Communications Biology|November 26, 2020
Large genome-wide association study identifies three novel risk variants for restless legs syndromeMaria Didriksen, Muhammad Sulaman Nawaz, Joseph Dowsett, et al.
Nature Communications|January 23, 2021
SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaquesYashavanth Shaan Lakshmanappa, Sonny R Elizaldi, Jamin W Roh, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2008
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionBrandon F Keele, Elena E Giorgi, Jesus F Salazar-Gonzalez, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
JAMA|September 2, 2021
Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021Jefferson M Jones, Mars Stone, Hasan Sulaeman, et al.
Science (New York, N.Y.)|December 9, 2020
Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemicLewis F Buss, Carlos A Prete, Claudia M M Abrahim, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay AreaDianna L Ng, Gregory M Goldgof, Brian R Shy, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Science Advances|July 31, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Nature Communications|September 18, 2020
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient bloodDianna L Ng, Gregory M Goldgof, Brian R Shy, et al.
Pageof 51